EUVIMEDEUVIMED entdecken
Open Access

Projected Impact and Cost-Effectiveness of Novel Molecular Blood-Based or Stool-Based Screening Tests for Colorectal Cancer

Uri Ladabaum iD, Ajitha Mannalithara iD, Robert E Schoen iD, Jason A Dominitz iD, David Lieberman

Annals of Internal Medicine · 2024-12 · 177 (12) · 1610-1620

DOI: 10.7326/annals-24-00910 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Internal Medicine, 2024-12. Verfasst von Uri Ladabaum und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology and Department of Medicine, Stanford University School of Medicine, Stanford, California (U.L., A.M.). Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cost-Benefit Analysis, Feces, Early Detection of Cancer. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cell-free DNA blood tests (cf-bDNA) and next-generation stool tests could change colorectal cancer (CRC) screening. OBJECTIVE: To estimate the clinical and economic impacts of novel CRC screening tests. DESIGN: Cost-effectiveness analysis using MOSAIC (Model of Screening and Surveillance for Colorectal Cancer). DATA SOURCES: Published data. TARGET POPULATION: Average-risk persons. TIME HORIZON: Ages 45 to 100 years. PERSPECTIVE: Health sector. INTERVENTION: Novel versus established CRC screening tests. OUTCOME MEASURES: Incidence and mortality of CRC, quality-adjusted life-years (QALYs), costs. RESULTS OF BASE-CASE ANALYSIS: For colonoscopy every 10 years, annual fecal immunochemical test (FIT), and triennial next-generation multitarget stool DNA, FIT-RNA, cf-bDNA (Guardant Shield), or cf-bDNA (Freenome), the relative rates (RRs) and 95% uncertainty intervals (UIs) versus no screening for CRC incidence were 0.21 (0.19 to 0.22), 0.29 (0.27 to 0.31), 0.33 (0.32 to 0.36), 0.32 (0.30 to 0.34), 0.58 (0.55 to 0.61) and 0.58 (0.55 to 0.60), respectively; the RRs for CRC death were 0.19 (0.17 to 0.20), 0.25 (0.23 to 0.27), 0.28 (0.27 to 0.30), 0.28 (0.26 to 0.30), 0.44 (0.42 to 0.47), and 0.46 (0.44 to 0.49), respectively. The cf-bDNA test (Shield; list price $1495) cost $89 600 ($74 800 to $102 300) per QALY gained versus no screening; alternatives were less costly and more effective. RESULTS OF SENSITIVITY ANALYSIS: Incremental costs exceeded incremental benefits when novel test intervals were shortened to 2 or 1 years. The cf-bDNA test matched FIT's impact on CRC mortality at 1.35 (1.30 to 1.40)-fold FIT's uptake rate, assuming equal colonoscopy follow-up. If persons who accept colonoscopy or stool tests shifted to cf-bDNA, CRC deaths increased. This adverse effect was overcome if every 3 such substitutions were counterbalanced by cf-bDNA uptake by 2 or more persons refusing alternatives, assuming equal colonoscopy follow-up. LIMITATION: Longitudinal test-specific participation patterns are unknown. CONCLUSION: First-generation cf-bDNA tests may deliver net benefit or harm, depending on the balance between achieving screening in persons who decline alternatives versus substituting cf-bDNA for more effective alternatives. PRIMARY FUNDING SOURCE: The Gorrindo Family Fund.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCost-Benefit AnalysisFecesEarly Detection of CancerQuality-Adjusted Life YearsOccult BloodColonoscopyHumansMiddle AgedAgedAged, 80 and overMass ScreeningFemaleMaleCell-Free Nucleic AcidsIncidence

Substanzen

Cell-Free Nucleic Acids

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology and Department of Medicine, Stanford University School of Medicine, Stanford, California (U.L., A.M.).
  • Division of Gastroenterology, Hepatology and Nutrition, and Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania (R.E.S.).
  • Veterans Administration Puget Sound Health Care System, Seattle; and Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington (J.A.D.).
  • Division of Gastroenterology and Hepatology, Oregon Health and Sciences University, Portland, Oregon (D.L.).

ORCID-Profile: Uri Ladabaum, Ajitha Mannalithara, Robert E Schoen, Jason A Dominitz

Förderung

  • NCI NIH HHS

Zitieren

APA

Ladabaum, U., Mannalithara, A., Schoen, R. E., Dominitz, J. A., & Lieberman, D. (2024). Projected Impact and Cost-Effectiveness of Novel Molecular Blood-Based or Stool-Based Screening Tests for Colorectal Cancer. Annals of Internal Medicine, 177(12), 1610-1620. https://doi.org/10.7326/annals-24-00910

Vancouver

Ladabaum U, Mannalithara A, Schoen RE, Dominitz JA, Lieberman D. Projected Impact and Cost-Effectiveness of Novel Molecular Blood-Based or Stool-Based Screening Tests for Colorectal Cancer. Annals of Internal Medicine. 2024;177(12):1610-1620. doi:10.7326/annals-24-00910

BibTeX
@article{Ladabaum2024,
  author = {Ladabaum, Uri and Mannalithara, Ajitha and Schoen, Robert E and Dominitz, Jason A and Lieberman, David},
  title = {Projected Impact and Cost-Effectiveness of Novel Molecular Blood-Based or Stool-Based Screening Tests for Colorectal Cancer},
  journal = {Annals of Internal Medicine},
  year = {2024},
  volume = {177},
  number = {12},
  pages = {1610--1620},
  doi = {10.7326/annals-24-00910}
}
Kostenlos starten →